Podcast

Speaking Out About Breast Implant-Associated Cancer

Author(s):

Kristie L. Kahl

In this episode of CURE® Talks Cancer, we spoke with an advocate who is raising awareness around the recent controversy surrounding a certain type of breast implant that is causing a rare type of lymphoma.

Imagine overcoming a breast cancer diagnosis and its treatment, yet in choosing reconstructive surgery with textured implants, finding out you may be at risk for a rare type of lymphoma.

Renee Ridgeley found herself in that exact situation.

Following the recent controversy with a Food and Drug Administration panel not banning these implants that are to blame for causing breast implant-associated anaplastic large-cell lymphoma, many women are speaking out about the issue.

In this week’s CURE® Talks Cancer podcast, we spoke with the patient advocate about her own experience and how women can learn more about their reconstruction options.

Related Videos
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine in the Department of Medicine at Beth Israel Deaconess Medical Center in Boston.
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of a woman with light shoulder-length hair, wearing rectangular glasses.
Image of man with grey hair.
Image of woman with blonde hair.
Image of woman with brown hair.
Related Content
"FDA" text.
January 17th 2025

FDA Approves Datroway for HR+, HER2- Breast Cancer

Alex Biese
Datroway has been approved for unresectable or metastatic HR+, HER2- breast cancer after endocrine therapy and chemotherapy.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of man with grey hair.
January 16th 2025

An Expert Breaks Down the Meaning of MRD Testing in Cancer Care

Ryan Scott
Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Illustration of woman with grey hair.
January 9th 2025

A New Year, A New Approach to Survivorship After Cancer

Felicia Mitchell
As I shift from an oncologist to a gynecologist for breast screenings, I examine both my reluctance to let go of the past and my hopes for the future.
An image of a doctor and patient talking with one another.
January 9th 2025

Minoxidil May Safely Aid in Hair Growth for Patients With Breast Cancer

Alex Biese
Low-dose oral minoxidil, the hair growth drug that is the active ingredient in Rogaine, may be safe and effective for patients with breast cancer.